Aeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a report published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Up 2.3 %

NASDAQ:AEZS opened at $3.75 on Friday. The firm has a market capitalization of $18.20 million, a price-to-earnings ratio of -1.46 and a beta of 1.35. Aeterna Zentaris has a twelve month low of $2.89 and a twelve month high of $10.99. The stock’s 50 day moving average price is $3.57 and its two-hundred day moving average price is $4.22.

Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) last issued its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.02). The firm had revenue of $1.86 million during the quarter, compared to the consensus estimate of $1.34 million. As a group, analysts anticipate that Aeterna Zentaris will post -3.04 earnings per share for the current year.

Aeterna Zentaris Company Profile

(Get Rating)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications.